Cytokinetics Inc to Discuss the Topline Results from SEQUOIA-HCM Transcript
Good morning and welcome, ladies and gentlemen, to the Cytokinetics conference call announcing the top line results of SEQUOIA-HCM. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen only mode company's request.
We will open the call for question and answers after the presentation. We will allow hoover up to one question per person. I would now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications, Investor Relations, please.
Welcome everyone, and thanks for joining us on our call today, which will focus on the top line results of SEQUOIA-HCM, the pivotal Phase three clinical trial of Affy Camden, our next-in-class cardiac myosin inhibitor. Robert Blum, our President and Chief Executive Officer, will begin with an overview of today's announcement. Then Fady Malik, our Executive Vice President of R&D, will present the top-line results. Robert will then provide closing remarks before we open
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |